Importantly, GBM poses unique challenges to effective small molecule targeting, with prior failures attributed to multifactorial etiologies including insufficient blood–brain barrier (BBB) penetration, intratumoral EGFR heterogeneity, and unique extracellular domain mutations that are distinct in location and function from those observed in other cancers.10–12. Here, EGFR is linked to glioblastoma.